Dialing into the frequency of real disruption, Amplifi Vascular just turned up the volume in medtech with a $6.8M Series A that feels less like another round and more like a prelude to a paradigm shift. Headquartered in Chesterfield, MO, this St. Louis-born innovator is tackling one of medicine’s most overlooked pain points: giving hemodialysis patients a fighting chance at better vascular access. Their Amplifi™ Vein Dilation System isn’t just a clever gadget, it’s a wearable, external blood pump engineered to do what biology alone can’t, prepping veins for surgical connection with precision and speed. Think of it as tuning the body’s plumbing before the main act begins.
The story goes deeper. Amplifi Vascular spun out from Artio Medical in 2023, carrying with it the DNA of Flow Forward Medical, the group that first imagined this approach. Now, with FDA IDE approval fresh in hand, they’re ready to launch the AMPLIFI-1 clinical investigation, an inflection point for the company and for patients who’ve been waiting too long for innovation that truly circulates. Leading this charge is Sean Morris, President & CEO, a 25+ year medtech veteran who built Veniti (acquired by Boston Scientific), guided Pulse Therapeutics, and held senior ranks at AngioDynamics. Alongside him is Paul Muller, CTO & GM, whose 25 years of R&D at Abbott, St. Jude, Thoratec & Guidant give this company its technical backbone. And running clinical and regulatory affairs, Erdie De Peralta ensures Amplifi doesn’t just move fast, it moves right.
The numbers speak for themselves. Roughly 2.3M people worldwide live with ESRD, relying on hemodialysis to survive. In the U.S., ~35% can’t even qualify for AVF surgery, and over 50% of those who do watch their fistulas fail to mature. The Amplifi System flips that narrative with data that matters, first-in-human studies showing rapid vein enlargement and early functional use, outcomes that translate into real hope for patients and less strain on healthcare systems.
While the lead investor in this round remains undisclosed, the significance is crystal clear: Amplifi Vascular has momentum. The funding fuels their next phase, clinical validation, market readiness, and the kind of execution that could redefine how AVFs are created and maintained. In an industry often slowed by red tape and risk aversion, Amplifi Vascular is flowing in the opposite direction, forward, fast, and focused.
So yeah, $6.8M might not sound like a tidal wave in Silicon Valley, but in medtech terms, it’s the right pressure at the right moment. When precision meets purpose, veins widen, access improves, and entire systems evolve. That’s Amplifi, turning circulation into innovation.
